Hua Chen to Medicare Part C
This is a "connection" page, showing publications Hua Chen has written about Medicare Part C.
Connection Strength
0.578
-
Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
Score: 0.177
-
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
Score: 0.173
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.057
-
Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
Score: 0.057
-
A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020 Apr; 99(16):e19603.
Score: 0.042
-
Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
Score: 0.040
-
Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case-Control Study. J Am Geriatr Soc. 2016 Feb; 64(2):394-400.
Score: 0.032